View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Pharmaceutical Investigation and CAPA System Assessment and Training

Pharmaceutical failure investigations and corrective and preventive action (CAPA) system weaknesses are consistently among the top most frequently cited regulatory observations and the top finding in US Food and Drug Administration (FDA) warning letters.

GMP certification programme for the US market

Pharmaceutical failure investigations and corrective and preventive action (CAPA) system weaknesses are consistently among the top most frequently cited regulatory observations and the top finding in US Food and Drug Administration (FDA) warning letters.

The most common regulatory concern is that investigations fail to thoroughly conduct root cause analysis (RCA) and fail to link corrective and preventative actions to the root causes identified. Often companies are cited for not considering the potential magnitude of an event or not considering other batches previously produced and possibly released into the market.

NSF’s programme brings together expertise from several disciplines and addresses each of these regulatory concerns through a comprehensive approach to pharmaceutical investigation system improvement.

The services also include investigation system assessment, root cause analysis training and investigator certification. Each of the elements can be selected individually or combined depending on your company’s needs and priorities.

Linking RCA analysis training to investigator certification has proven to provide sustainable results and an impressive return on investment (ROI). By finding and addressing root cause, pharmaceutical failure investigation rates drop and the resulting savings more than offset the company investment in training and assessment.

NSF Pharma Biotech's CEO Martin Lush recently had a meeting with a CEO to help solve his company’s pain points.
Making a case for good manufacturing practice (GMP) certification of an excipient manufacturer should be a straightforward exercise since the benefits appear so clear cut...
Risk management across a global supply chain has never been a stronger factor in assuring economic success than it is now.
The heart of the European Union (EU) regulation of in vitro diagnostic medical devices (IVDs) lies in allowing market access to IVDs that offer clinical...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology